Cousins Properties Incorporated (NYSE:CUZ):
Cousins Properties Incorporated (NYSE:CUZ) ended its previous trading session at $8.02 with the Loss of -1.96%. The company’s market cap is $3.37 Billion, and the average volume is $4.79 Million. The 52-Week High range of the stock is $8.82, while the 52-week low range is $6.62. The stock touched its 52-Week High on Feb 9, 2017 and 52-Week Low on Mar 10, 2016. The Price to Sales (P/S) of the stock is 13.2, while P/B (Price to Book) stands at 1.31. When we look at the Volatility of the company, Week Volatility is at 2.29% whereas Month Volatility is at 1.86%.
For the ongoing Fiscal Quarter, 1 analysts have an average earnings forecast of $0.03 per share. According to the Analysts, the Low Earnings estimate for the current quarter is $0.03, while the High earnings estimate is $0.03.Comparatively, EPS for the same quarter last year was $0.
According to 4 analysts, the Average Revenue Estimate for the current Fiscal quarter is $116.14 Million and the Low Revenue estimate is $111.8 Million, while the High Revenue estimate is $124.05 Million.
According to the Recommendation Trends of the stock polled by Zacks Investment Research for this month, the company has a consensus recommendation of 2.67 out of the scale from 1 to 5 where 1 stands for Strong Buy and 5 means Strong Sell.
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM):
Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) shares declined -10.21% and ended the day at $0.61. Its 52-week high and low range is between $0.76 and $0.28. The stock has its 52-Week High on Mar 3, 2017 and 52-Week Low on Jan 30, 2017. The company’s outstanding shares are 239.74 Million. The volume of the company in the last trading session was 4.19 Million. The stock has a market cap of 146.39 Million. The Stock shows P/E value of 0 and Forward P/E of 0.
According to Finviz reported data, The SMA20 of the stock is at 17.42%, SMA50 is 56.16 percent, while SMA200 is 61.92%. The stock is currently has its Return on Assets (ROA) value of -43.9 Percent. The Return on Investment and Return on Equity (ROE) values are -112.5 percent and -101 percent, respectively.
The company’s ATR (Average True Range) is 0.05. The Weekly Volatility is 8.40 percent and the Monthly Volatility is 11.76 percent.
When we look at the Analyst Recommendations of the stock, the company has 1 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.
The stock has a high price target of $1 according to consensus of 1 analyst. The company has a Low Price Target of $1 and the Mean Target of $1, according to the Brokers.
Peregrine Pharmaceuticals, Inc.’s Average Earnings Estimate for the current quarter is $-0.03, according to consensus of 1 analysts. The low EPS estimate is $-0.03, while the high EPS estimate is $-0.03.
Average Revenue Estimate of the company for the current Fiscal Quarter is $14 Million, according to consensus of 1 analysts. The higher end of the revenue estimate is $14 Million and the lower end is $14 Million.